BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2001

View Archived Issues

Novel chimeric protein with potential application as HIV therapy available for licensing from NIH

Read More

Licensing opportunity from NIH: beta2-microglobulin fusion proteins

Read More

Bayer and m-phasys collaborate on protein-targeting drug discovery tools

Read More

Preclinical pipeline at Faes includes new antidepressant and antipsychotic agents

Read More

Nerve injury-induced gene discovered by Washington University scientists

Read More

GlaxoSmithKline and Taisho collaborate on smoking control products

Read More

Antisoma enters supply agreement for thioplatin

Read More

Genentech highlights business and product events for Q2 2001

Read More

Liposome-mediated eNOS gene transfection for reducing myocardial ischemia-reperfusion injury

Read More

New England Journal of Medicine publishes pivotal data for Fabrazyme

Read More

Aventis licenses new solid tumor treatment from Ajinomoto

Read More

Significant clinical antileukemic activity demonstrated for signal transduction inhibitor

Read More

Antigenics finalizes acquisition of Aronex; broadens pipeline

Read More

Alpha1A-adrenoceptor blockade not associated with improvement in MED

Read More

Vion awarded SBIR grant to support development of sulfonyl hydrazine prodrugs

Read More

Vevesca enters U.S. trial for Gaucher's disease

Read More

Mozenavir vs. indinavir in antiretroviral-naive HIV patients

Read More

Pharmacia receives nonapprovable letter from FDA for analgesic product

Read More

Dynamics of anti-HIV response to GPG-NH2 examined after oral and s.c. dosing

Read More

Consensus granted NIH funding to support research on HIV entry inhibitors

Read More

Immunex advances IL-1 regulator to clinical trials

Read More

MedImmune evaluates Vitaxin in new clinical trial in colorectal cancer patients

Read More

Treatment of mild cognitive impairment with glucocorticoid receptor antagonists

Read More

Australian researchers identify new tumor suppressor gene

Read More

HIV protease inhibitors designed at Merck with improved activity against HIV mutants

Read More

Preparation and use of CSBP/p38 kinase inhibitors in respiratory and other inflammatory disorders

Read More

Sepracor preparing for NDA submission of insomnia drug candidate

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing